Passively Transferred Myasthenia Gravis: Protection of Mouse Endplates by Fab Fragments from Human Myasthenic IgG

Overview

Journal J Neurol Neurosurg Psychiatry

Publisher BMJ Publishing Group

Specialties Neurology
Neurosurgery
Psychiatry

Date 1980 Sep 1

PMID 6252294

Citations 9

Authors

K V Toyka

B Lowenadler

K Heininger

U A Besinger

K L Birnberger

E Heilbronn

Affiliations

Soon will be listed here.

Abstract

Using the mouse passive transfer model, the effects of purified human myasthenic immunoglobulin G and of the monovalent Fab fragment on neuromuscular junctions were investigated. Treatment with IgG markedly reduced amplitudes of miniature endplate potentials. When Fab fragments were transferred alone or with subsequent addition of IgG no neuromuscular transmission block was induced. Myasthentic IgG and Fab were specifically demonstrated at the neuromuscular junctions by immunohistochemistry. On electronmicroscopy endplate structure was normal in transfer experiments using IgG for up to 30 days. It is suggested that Fab fragments bind to acetylcholine receptors without affecting transmission and protect them from the attack of complete IgG antibodies.

Citing Articles

Glycine receptor autoantibodies disrupt inhibitory neurotransmission.

Crisp S, Dixon C, Jacobson L, Chabrol E, Irani S, Leite M Brain. 2019; 142(11):3398-3410.

PMID: 31591639 PMC: 6821286. DOI: 10.1093/brain/awz297.

Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys.

Losen M, Labrijn A, van Kranen-Mastenbroek V, Janmaat M, Haanstra K, Beurskens F Sci Rep. 2017; 7(1):992.

PMID: 28428630 PMC: 5430546. DOI: 10.1038/s41598-017-01019-5.

Autoimmune synaptopathies.

Crisp S, Kullmann D, Vincent A Nat Rev Neurosci. 2016; 17(2):103-17.

PMID: 26806629 DOI: 10.1038/nrn.2015.27.

Guidelines for pre-clinical assessment of the acetylcholine receptor--specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs.

Kusner L, Losen M, Vincent A, Lindstrom J, Tzartos S, Lazaridis K Exp Neurol. 2015; 270:3-10.

PMID: 25743217 PMC: 4466131. DOI: 10.1016/j.expneurol.2015.02.025.

Myasthenia gravis as a prototype autoimmune receptor disease.

Hoedemaekers A, Van Breda Vriesman P, De Baets M Immunol Res. 1997; 16(4):341-54.

PMID: 9439759 DOI: 10.1007/BF02786398.

References

Karnovsky M . The ultrastructural basis of capillary permeability studied with peroxidase as a tracer. J Cell Biol. 1967; 35(1):213-36. PMC: 2107108. DOI: 10.1083/jcb.35.1.213. View

Engel A, Santa T . Histometric analysis of the ultrastructure of the neuromuscular junction in myasthenia gravis and in the myasthenic syndrome. Ann N Y Acad Sci. 1971; 183:46-63. DOI: 10.1111/j.1749-6632.1971.tb30741.x. View

Ruddy S, Gigli I, Austen K . The complement system of man. I. N Engl J Med. 1972; 287(10):489-95. DOI: 10.1056/NEJM197209072871005. View

Fertuck H, Salpeter M . Localization of acetylcholine receptor by 125I-labeled alpha-bungarotoxin binding at mouse motor endplates. Proc Natl Acad Sci U S A. 1974; 71(4):1376-8. PMC: 388231. DOI: 10.1073/pnas.71.4.1376. View

Toyka K, Brachman D, Pestronk A, Kao I . Myasthenia gravis: passive transfer from man to mouse. Science. 1975; 190(4212):397-9. DOI: 10.1126/science.1179220. View

Arend W, Silverblatt F . Serum disappearance and catabolism of homologous immunoglobulin fragments in rats. Clin Exp Immunol. 1975; 22(3):502-13. PMC: 1538449. View

Albuquerque E, Rash J, Mayer R, Satterfield J . An electrophysiological and morphological study of the neuromuscular junction in patients with myasthenia gravis. Exp Neurol. 1976; 51(3):536-63. DOI: 10.1016/0014-4886(76)90179-5. View

LAMBERT E, Lindstrom J, Lennon V . End-plate potentials in experimental autoimmune myasthenia gravis in rats. Ann N Y Acad Sci. 1976; 274:300-18. DOI: 10.1111/j.1749-6632.1976.tb47694.x. View

Heilbronn E, Mattsson C, Thornell L, Sjostrom M, Stalberg E, Hilton-Brown P . Experimental myasthenia in rabbits: biochemical, immunological, electrophysiological, and morphological aspects. Ann N Y Acad Sci. 1976; 274:337-53. DOI: 10.1111/j.1749-6632.1976.tb47696.x. View

10.

Toyka K, Drachman D, Griffin D, Pestronk A, Winkelstein J, Fishbeck K . Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med. 1977; 296(3):125-31. DOI: 10.1056/NEJM197701202960301. View

11.

Kao I, Drachman D . Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science. 1977; 196(4289):527-9. DOI: 10.1126/science.850793. View

12.

Engel A, LAMBERT E, HOWARD F . Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc. 1977; 52(5):267-80. View

13.

Appel S, Anwyl R, McAdams M, Elias S . Accelerated degradation of acetylcholine receptor from cultured rat myotubes with myasthenia gravis sera and globulins. Proc Natl Acad Sci U S A. 1977; 74(5):2130-4. PMC: 431089. DOI: 10.1073/pnas.74.5.2130. View

14.

Drachman D . Myasthenia gravis (first of two parts). N Engl J Med. 1978; 298(3):136-42. DOI: 10.1056/NEJM197801192980305. View

15.

Drachman D, Angus C, Adams R, Michelson J, Hoffman G . Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med. 1978; 298(20):1116-22. DOI: 10.1056/NEJM197805182982004. View

16.

Lennon V, Seybold M, Lindstrom J, Cochrane C, Ulevitch R . Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med. 1978; 147(4):973-83. PMC: 2184243. DOI: 10.1084/jem.147.4.973. View

17.

Lefvert A, Bergstrom K, Matell G, OSTERMAN P, Pirskanen R . Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry. 1978; 41(5):394-403. PMC: 493044. DOI: 10.1136/jnnp.41.5.394. View

18.

Stanley E, Drachman D . Effect of myasthenic immunoglobulin on acetylcholine receptors of intact mammalian neuromuscular junctions. Science. 1978; 200(4347):1285-7. DOI: 10.1126/science.663610. View

19.

Heilbronn E, Stalberg E . The pathogenesis of myasthenia gravis. J Neurochem. 1978; 31(1):5-11. DOI: 10.1111/j.1471-4159.1978.tb12426.x. View

20.

Toyka K, Birnberger K, Anzil A, Schlegel C, Besinger U, STRUPPLER A . Myasthenia gravis: further electrophysiological and ultrastructural analysis of transmission failure in the mouse passive transfer model. J Neurol Neurosurg Psychiatry. 1978; 41(8):746-53. PMC: 1083392. DOI: 10.1136/jnnp.41.8.746. View